2023.09.19【呼吸器疾患 非小細胞肺がん(NSCLC)】米国CMEコンテンツ日本語版を制作


Quickfire Updates from Chicago: What’s New for EGFR TKI Refractory and Resistant Non-Small Cell Lung Cancer?

David Planchard, MD, PhD
Associate Professor of Medicine
Department of Medical Oncology
Thoracic Unit
Institut Gustave Roussy
Villejuif, France

Natasha B. Leighl, MD, MMSc
Lung Site Lead, Medical Oncology
Princess Margaret Cancer Centre
OSI Pharmaceuticals Foundation Chair, PMC Foundation
Professor, Department of Medicine, University of Toronto
Adjunct Professor, Dalla Lana School of Public Health
Toronto, Canada

MEDuLiTe | シカゴからの一問一答形式による最新情報 ~EGFRチロシンキナーゼ阻害薬(EGFR-TKI)難治性・抵抗性非小細胞肺がん(NSCLC)をめぐる新たな知見とは?~ (